European scientists have made ground-breaking discoveries for improving the efficiency of the production of pharmaceuticals through plant biotechnology. Biotechnological production offers a cost-effective and environmentally friendly alternative to the chemical synthesis of rare and complex ... more
VTT and GE Healthcare developing novel biomarkers to predict Alzheimer’s disease
28-06-2012: Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.
Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues.
In 2010 GE Healthcare entered into “biosignatures initiative” alliance with Janssen Pharmaceutica N.V. (Janssen) to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.
VTT’s research professor Matej Orešič said: “We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE’s and Janssen’s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.”
VTT Technical Research Centre of Finland has developed a lightweight, handheld, ultra-precision hyperspectral camera for the detection of skin cancers and their precursors. From the surface of the skin, the camera recognises early stages of cancer that are invisible to the naked eye. Collab ... more
Gas sensors developed in a European project now enable the implementation of cheaper and smaller instruments with equal or higher speed and sensitivity than current laboratory-grade instruments. Production of super-sensitive and portable measuring devices is made possible by a photo-acousti ... more
The European Association for Research on Services, RESER, will hold its 24th International Conference in Helsinki, Finland. RESER conference is a multidisciplinary forum, where researchers in economics, geography, sociology, management, marketing and many other disciplines meet to share the ... more
Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The ... more
GE Healthcare, a unit of General Electric Company, announced that it has entered into a Strategic Alliance Agreement with FUJIFILM Corporation. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare. The products will be sold ... more
Tecan and GE Healthcare are working together to bring increased quality and efficiency to process development. The collaboration between the two suppliers focuses on high throughput screening of protein purification conditions, using the combination of Tecan’s Freedom EVO® automated worksta ... more
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2Almost as sensitive as a dog's nose
- 3Three-dimensional model of bacterium
- 4Raman keeps lipstick evidence in the bag
- 5Do you want to know how much caffeine is in your drink?
- 6Breakthrough in DNA editing technology
- 73D IR images now in full color
- 8PIAB announces new Chief Executive Officer
- 9‘Forensic fingers’ for crime scene investigation
- 10Raman pixel by pixel
- Polyplus-transfection and the National Institute of Health sign a research l ...
- MolecularHealth Partners with GATC Biotech for Genetic Sequencing Technology ...
- Lonza signs exclusive agreement with Index Ventures
- Evonik and LanzaTech working on bio-processed precursors for specialty plastics
- Roche and Molecular Partners enter into alliance
- Sustainable production of pharmaceutical compounds
- Hyperspectral camera shows promising results in detection of skin field cancerization
- Dr. Georg Meissner appointed Managing Director, SPECIM Spectral Imaging Ltd. Oy
- Formation of nanoparticles can now be studied molecule-by-molecule
- Sensor technology for efficient and portable gas detection devices